Mass spectrometry is a crucial tool for the structural and physicochemical characterization of your biopharmaceutical. BioPharmaSpec scientists pioneered many of the standard methodologies used in laboratories to characterize biopharmaceuticals such as recombinant proteins, antibodies, antibody drug conjugates (ADCs), fusion proteins, bispecifics and biosimilars.
Mass spectrometry measures the mass to charge (m/z) ratio of peptides, proteins, glycoproteins and oligosaccharides allowing an accurate determination of molecular weight. In many mass spectrometric analyses, energy induced fragmentation can be used to provide additional structural information.
All mass spectrometers comprise the following components:
- an ionization source e.g. Matrix Assisted Laser Desorption Ionisation (MALDI) and Electrospray ionisation (ESI). Both of these create quasimolecular ions from the component of interest in the gaseous phase,
- a mass analyzer, which accurately measures the m/z ratios of the ionized species and
- a detector to provide the response.
BioPharmaSpec uses mass spectrometry to provide high-quality characterization information for biopharmaceuticals including intact molecular weight analysis, primary (de novo) amino acid sequence confirmation, peptide mapping including analysis of Post Translational Modifications (PTMs), disulfide bridge analysis and carbohydrate structure assessments such as monosaccharide composition, monosaccharide Linkage and oligosaccharide profiling.